Patricia Pérez-Galán
Publicacions destacades
-
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Autors:Referència: Blood Cancer Journal 2024. -
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
Autors:Referència: Journal For Immunotherapy Of Cancer 2023. -
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
Autors:Referència: Leukemia 2023. -
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Autors:Referència: Leukemia 2021. -
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
Autors:Referència: Cancers 2021. -
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax
Autors:Referència: Blood Advances 2020. -
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Autors:Referència: Haematologica 2020. -
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Autors:Referència: Haematologica 2017. -
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia
Autors:Referència: Clinical Cancer Research 2017. -
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Autors:Referència: Clinical Cancer Research 2014.
Projectes destacats
-
Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)
Investigador/a principal: Patricia Pérez GalánCodi: EFA 123/1Durada: 01/01/2024 - 31/12/2025 -
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk
Investigador/a principal: Patricia Pérez GalánFinançador: Janssen PharmaceuticalsDurada: 01/01/2020 - 31/12/2020 -
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET
Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez GalánFinançador: Ministerio de Economia y Competitividad (MINECO)Codi: SAF 2017- 88275-RDurada: 01/01/2018 - 31/12/2020 -
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).
Investigador/a principal: Patricia Pérez GalánFinançador: INTERREG V-POCTEFACodi: EFA281/16Durada: 01/01/2018 - 31/12/2021 -
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention
Investigador/a principal: Patricia Pérez GalánFinançador: Ministerio de Economía y CompetitividadCodi: SAF 2014/57708RDurada: 01/01/2015 - 01/01/2018